m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG04214)
Name
PF-04236921
Status
Phase 2
TTD Drug ID
D06NXG
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Interleukin-6 (IL6)
Methyltransferase-like 14 (METTL14)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Interleukin-6 (IL6) is a therapeutic target for PF-04236921. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of PF-04236921 through regulating the expression of Interleukin-6 (IL6). [1], [2]
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Interleukin-6 (IL6) is a therapeutic target for PF-04236921. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of PF-04236921 through regulating the expression of Interleukin-6 (IL6). [2], [3]
YTH domain-containing protein 2 (YTHDC2)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Interleukin-6 (IL6) is a therapeutic target for PF-04236921. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of PF-04236921 through regulating the expression of Interleukin-6 (IL6). [2], [4]
References
Ref 1 Mettl14 mediates the inflammatory response of macrophages in atherosclerosis through the NF-KappaB/IL-6 signaling pathway. Cell Mol Life Sci. 2022 May 22;79(6):311. doi: 10.1007/s00018-022-04331-0.
Ref 2 Efficacy and safety of olokizumab in patients with rheumatoid arthritis with an inadequate response to TNF inhibitor therapy: outcomes of a randomised Phase IIb study. Ann Rheum Dis. 2014 September; 73(9): 1607-1615.
Ref 3 METTL3 Promotes Activation and Inflammation of FLSs Through the NF-KappaB Signaling Pathway in Rheumatoid Arthritis. Front Med (Lausanne). 2021 Jul 6;8:607585. doi: 10.3389/fmed.2021.607585. eCollection 2021.
Ref 4 The m(6)A reader YTHDC2 is essential for escape from KSHV SOX-induced RNA decay. Proc Natl Acad Sci U S A. 2022 Feb 22;119(8):e2116662119. doi: 10.1073/pnas.2116662119.